Orasure Technologies Inc. (OSUR)
OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.22 per share a year ago.
OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock?
OraSure (OSUR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy OraSure Technologies (OSUR) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation.
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is OraSure Technologies (OSUR) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.27 per share a year ago.
OraSure: An NCAV Diamond In The COVID Rough
OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value (NCAV). At the same time, OraSure has a stable operational history with consistent normalized cash flow margins.
Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc
On September 30, 2024, Neuberger Berman Group LLC, a prominent investment firm, made a significant addition to its investment portfolio by acquiring 3,927,692 shares of OraSure Technologies Inc (OSUR, Financial). This transaction, executed at a price of $4.27 per share, marks a notable increase in the firm's holdings in the medical devices sector.
OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript
OraSure Technologies Inc (NASDAQ:OSUR ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President and Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Andrew Cooper - Raymond Jones Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Incorporated 2024 Second Quarter Earnings Conference Call.
